---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-157038"
form_type: "8-K/A"
ticker: "SNSE"
cik: "0001829802"
company_name: "Sensei Biotherapeutics, Inc."
filed_at: "2026-04-15T23:59:59+00:00"
generated_at: "2026-05-15T06:09:41.933059+00:00"
event_type: "m_and_a"
sentiment: "negative"
materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sensei Biotherapeutics files audited Faeth financials; net loss $16M in 2025, going-concern doubt

## Summary
- Faeth net loss $16.0M in 2025 ($18.3M in 2024); accumulated deficit $77.7M at Dec 31, 2025.
- R&D expenses $12.0M (2025) vs $14.1M (2024); cash & equivalents $20.4M at Dec 31, 2025.
- Auditor cites substantial doubt about going concern due to potential cash payments from $200M PIPE Series B preferred.
- Acquisition of Faeth closed Feb 17, 2026; concurrent $200M PIPE closed Feb 20, 2026.

## SEC filing metadata
- accession: 0001193125-26-157038
- form_type: 8-K/A
- ticker: SNSE
- cik: 0001829802
- company_name: Sensei Biotherapeutics, Inc.
- filed_at: 2026-04-15T23:59:59+00:00
- event_type: m_and_a
- sentiment: negative
- materiality_score: 0.75
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829802/000119312526157038/0001193125-26-157038-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829802/000119312526157038/d40329d8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-157038
- JSON: https://secwatch.observer/filing/0001193125-26-157038.json
- Plain text: https://secwatch.observer/filing/0001193125-26-157038.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.